Analysis: Still wary of Russian vaccine, Brazil clears its own study for more data
FILE PHOTO: Doses of the Sputnik V vaccine against the coronavirus disease (COVID-19) are seen at a vaccination centre in Zilina, Slovakia June 7, 2021. REUTERS/Radovan Stoklasa reuters tickers
This content was published on June 9, 2021 - 15:15
June 9, 2021 - 15:15
By Lisandra Paraguassu
BRASILIA (Reuters) - Russian vaccine developers cheered hard-won access to Brazil s market last week, but with less than a million doses cleared for import, public health experts say the approval is more like a late-stage trial for the Sputnik V shot.
Late Friday, Brazilian health regulator Anvisa, which was under pressure from state governors and the country s Supreme Court, ruled that states could import the Russian COVID-19 vaccine, but included some 20 strict conditions.
BRASILIA, June 5 ― Brazilian health regulator Anvisa yesterday gave the green light for states to import the Russian Covid-19 vaccine Sputnik V, but with conditions attached. Anvisa's board voted 4-1 to grant the conditional approval after more than seven hours of deliberation, following the.
BRASILIA: Brazilian health regulator Anvisa on Friday gave the green light for states to import the Russian COVID-19 vaccine Sputnik V, but with conditions attached. Anvisa’s board voted 4-1 to grant the conditional approval after more than seven hours of deliberation, following the recommendation of its technical staff earlier in the day. Anvisa also voted to approve, again
Russia's sovereign wealth fund said on Friday that Paraguay had become the eighth country outside Russia to approve the Sputnik V coronavirus vaccine, developed by Moscow's Gamaleya Institute, for domestic use.
BBC News
Published
image copyrightGetty Images
India has ordered 300 million doses of an unapproved coronavirus vaccine amid a devastating second wave.
The unnamed vaccine from Indian firm Biological E is in Phase 3 trials, and had showed promising results in the first two phases, the federal government said in a statement.
The $206m order is the first India has signed for a jab that has not received emergency approval.
This comes as the country struggles to speed up its lagging vaccine drive.
India has administered just over 220 million jabs so far although much of its 1.4 billion population is now eligible for the vaccine. Less than 10% of the country has received at least one dose of the vaccination, largely because of a severe shortage of doses.